Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glembatumumab vedotin + pembrolizumab
- Development stage
- Discontinued
- Lead developer
- Celldex Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination therapy of **glembatumumab vedotin**, an antibody-drug conjugate targeting glycoprotein NMB (gpNMB), and **pembrolizumab**, a humanized monoclonal antibody targeting the programmed cell death-1 (PD-1) receptor. Glembatumumab vedotin delivers the cytotoxic agent monomethyl auristatin E (MMAE) to gpNMB-expressing tumor cells to induce cell death. Pembrolizumab blocks PD-1, enabling T cells to mount an anti-tumor immune response. This combination was investigated for advanced melanoma, but development was discontinued after disappointing trial results.
- Other names
- glembatumumab vedotin and pembrolizumab
02
Targets
GPNMB (Glycoprotein NMB)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on glembatumumab vedotin + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glembatumumab vedotin + pembrolizumab.